Navigation Links
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD

Phase III clinical trial may commence shortly

CARMIEL, Israel, April 18, 2007 /PRNewswire-FirstCall/ --- Protalix BioTherapeutics, Inc. today announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.

The FDA has allowed the Company to directly initiate Phase III based upon the results of the Company's pre clinical and Phase I clinical trials of prGCD. The Company presented the completed data from its Phase I clinical trial at the European Working Group of Gaucher Disease (WEGGD) in Cambridge, United Kingdom in July 2006.

The Company hopes to commence the Phase III clinical trial shortly. The trial will take place in centers in the United States, Israel, where approval from the Israeli Ministry of Health has been received, and other locations worldwide. The study will initially consist of male and female adult patients with Gaucher Disease.

David Aviezer, Ph.D., President and Chief Executive Officer of Protalix BioTherapeutics, commented, "The receipt of the FDA's approval to initiate a Phase III clinical trial of prGCD represents an important milestone in the development of this product, and we are excited about the progress we have made thus far. Following the success of our Phase I trial and our promising pre clinical and biochemical data, we believe that we will continue to see positive results from our patients in Phase III."

Dr. Aviezer continued, "We remain deeply committed to the development of a treatment for Gaucher Disease and are excited by the opportunity to commence the Phase III trial and working with the medical experts and patient community."

About
'"/>




Page: 1 2 3

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
3. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/27/2008)...l, expected by mid-2009 - - Data from second Phas...KVILLE, Md., Aug. 27 /- Hum...nounced it has completed enrollment,and initial do...3,randomized clinical trials of LymphoStat-B(R) (b...rythematosus (SLE). Belimumab is being developed b...
(Date:8/26/2008)... SYNTAX clinical trial, NATICK, Mass., Aug. 26 /P...ion (NYSE: BSX ) today announced the schedule of ... at the European Society of Cardiology,Congress 20...nich, Germany., The Company plans to announce 12-...ercutaneous coronary intervention (PCI) using the ...
(Date:8/26/2008)...afore Pharmaceuticals Inc.,presented data at the S...s,in Cancer in Washington, D.C., announcing the di...that demonstrate significant anticancer,activity i...olecular scaffold has been developed using,computa... kinase inhibitors,as well as isoform-selective sm...
(Date:8/26/2008)...- Healthpoint today announced,that it has initiate...f a,widely prescribed enzymatic debriding agent on... pilot study was prompted, in part, by clinical re...rs and beneficial healing,properties associated wi...he findings from the peer-reviewed literature, as ...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 1Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 2Roches Vidal Honored as 2008 HBA Rising Star 18911 1Roches Vidal Honored as 2008 HBA Rising Star 18911 2American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 1American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 2International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 1International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 2
...-Apr 16, 2007 - Amgen,(Nasdaq:AMGN) today presente...cebo-controlled Phase 3 study evaluating the,effic...r the,treatment of anemia in patients with active ...("the 103 study"). Aranesp is not,approved for use...ts were presented in an oral session at the 2007 A...
... approach for the treatment,of early and metastati...wswire-FirstCall/ - AEterna,Zentaris Inc. , a glob... endocrine therapy and oncology, today presented a...ormone-releasing,hormone (GHRH) antagonist JMR-132... Cancer Research (AACR) Annual Meeting being held,...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ty Massey Cancer Center have discovered a process ...cules containing platinum, which causes HIV and ca...the researchers to develop new drugs to fight HIV ...argeting proteins known as zinc fingers. In the M...
...at funds for wheelchair service from NHS has not r...ildren are losing out their hope due to lack of a ...wheelchair with most basic parts, was given due to...sh Me Around!’, highlights. Thus it calls for Gove...
...n (NBA) have entered into a partnership to support.... // The campaign, 'Unite for Children, Unite aga.../AIDS on children as well as impeding further spre...e know that our sport, indeed all sports, has an e...
...hetamine-like stimulant has a calming effect on ch...er (ADHD) // . A new study undertaken on rats, se...ly used to treat ADHD, appears to work by tweaking...acted by any stimuli from the outside world. The s...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: